BioInvent International AB (Nasdaq Stockholm: BINV; 0H22), a Lund, Sweden-based clinical-stage biotech specialising in immune-modulatory antibodies for cancer therapy, has announced that members of its management team will participate in five investor conferences across Europe during November and December 2026. The events span four countries and include both one-on-one meetings and company presentations. The schedule reflects active investor outreach by the company as it advances multiple antibody candidates through Phase 1/2 clinical trials targeting haematological cancers and solid tumours.

Key Points

  • BioInvent International AB (Nasdaq Stockholm: BINV; 0H22) is a clinical-stage biotech headquartered in Lund, Sweden
  • Management will attend five investor conferences between 9 November and 8 December 2026
  • Events include BIO-Europe in Cologne, the Jefferies Global Healthcare Conference in London, and the DNB Carnegie Nordic Healthcare Conference in Oslo
  • Investors may watch for updates on BioInvent's clinical pipeline and any new partnering or licensing disclosures arising from these engagements

BioInvent's Five-Conference European Schedule from Cologne to Stockholm

The company's conference schedule opens with BIO-Europe 2026 in Cologne, Germany, on 9–11 November, conducted via one-on-one meetings. This is immediately followed by the Aktiespararna Digital Life Science night in Lund on 12 November, where BioInvent will deliver a company presentation. Management will then participate in one-on-one meetings at the 2026 Jefferies Global Healthcare Conference in London from 16–19 November, before travelling to Oslo for the DNB Carnegie Nordic Healthcare Conference on 24 November. The schedule concludes with a company presentation at the Di Investor Summit Life Science in Stockholm on 8 December 2026.

F.I.R.S.T™ Platform and Clinical Pipeline Underpin BioInvent's Investor Story

BioInvent's proprietary F.I.R.S.T™ technology platform is central to its investor narrative, as it simultaneously identifies both biological targets and the antibodies that bind to them, enabling the discovery of first-in-class immuno-modulatory candidates. The company currently has drug candidates in ongoing Phase 1/2 clinical trials for haematological cancers and solid tumours. This pipeline, developed entirely in-house, forms the basis of BioInvent's licensing and partnering opportunities with large pharmaceutical companies, making these conferences strategically relevant for business development as well as investor communications.

Revenue Model Combining Licensing, Collaborations, and Antibody Manufacturing

BioInvent generates revenues through two principal streams: research collaborations and licence agreements with multiple top-tier pharmaceutical companies, and the production of antibodies for third parties through its fully integrated manufacturing unit based in Lund. This dual revenue model distinguishes BioInvent from pure-play clinical-stage biotechs and provides a degree of commercial activity alongside its development programmes. Investors attending or monitoring the upcoming conferences may focus on whether any new collaboration or licensing arrangements are discussed, given the business development format of several one-on-one meeting events on the schedule.